Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Prateek Mathur, Swati Sharma, Shruti Rawal, Bhoomika Patel & Mayur M. Patel. (2020) Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity. Journal of Liposome Research 30:2, pages 182-196.
Read now
Read now
Rafid Salim Jabir, Gwo Fuang Ho, Muhammad Azrif Bin Ahmad Annuar & Johnson Stanslas. (2018) Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients. Biomarkers 23:2, pages 142-146.
Read now
Read now
I. M. H. Soenderstrup, A. V. Laenkholm, M. B. Jensen, J. O. Eriksen, A. M. Gerdes, T. V. O. Hansen, T. A. Kruse, M. J. Larsen, I. S. Pedersen, M. Rossing, M. Thomassen & B. Ejlertsen. (2018) Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. Acta Oncologica 57:1, pages 95-101.
Read now
Read now
Li Zhang & Na Zhang. (2013) How nanotechnology can enhance docetaxel therapy. International Journal of Nanomedicine 8, pages 2927-2941.
Read now
Read now
Kenneth Geving Andersen, Maj-Britt Jensen, Henrik Kehlet, Rune Gärtner, Lise Eckhoff & Niels Kroman. (2012) Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. Acta Oncologica 51:8, pages 1036-1044.
Read now
Read now
Articles from other publishers (26)
Cathrine F. Hjorth, Dóra K. Farkas, Lidia Schapira, Mark R. Cullen, Henrik T. Sørensen & Deirdre Cronin-Fenton. (2023) Risk of primary haematologic cancers following incident non-metastatic breast cancer: A Danish population-based cohort study. Cancer Epidemiology 82, pages 102311.
Crossref
Crossref
Cathrine F. Hjorth, Per Damkier, Tore B. Stage, Søren Feddersen, Stephen Hamilton-Dutoit, Bent Ejlertsen, Timothy L. Lash, Henrik Bøggild, Henrik T. Sørensen & Deirdre Cronin-Fenton. (2023) The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer. Cancer Chemotherapy and Pharmacology 91:2, pages 157-165.
Crossref
Crossref
Rui Wang, Jun Shen, Huanhuan Yan, Xitao Gao, Tianfu Dong, Shuqin Li, Peishun Wang & Jun Zhou. (2022) Dosimetric comparison between intensity-modulated radiotherapy and volumetric-modulated arc therapy in patients of left-sided breast cancer treated with modified radical mastectomy. Medicine 101:2, pages e28427.
Crossref
Crossref
Célia Matta, Laurence Meyer, Ayikoe-Guy Mensah-Nyagan & Omar Taleb. (2020) Behavioral, Electrophysiological, and Histological Characterization of a New Rat Model for Neoadjuvant Chemotherapy–Induced Neuropathic Pain: Therapeutic Potential of Duloxetine and Allopregnanolone Concomitant Treatment. Neurotoxicity Research 38:1, pages 145-162.
Crossref
Crossref
Takumi Sakurada, Sanako Bando, Yoshito Zamami, Kenshi Takechi, Masayuki Chuma, Mitsuhiro Goda, Yasushi Kirino, Toshimi Nakamura, Kazuhiko Teraoka, Masami Morimoto, Akira Tangoku & Keisuke Ishizawa. (2019) Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study. Cancer Chemotherapy and Pharmacology 84:5, pages 1107-1114.
Crossref
Crossref
Hendrik Rathke, Clemens Kratochwil, Ralph Hohenberger, Frederik Lars Giesel, Frank Bruchertseifer, Paul Flechsig, Alfred Morgenstern, Matti Hein, Peter Plinkert, Uwe Haberkorn & Olcay Cem Bulut. (2018) Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. European Journal of Nuclear Medicine and Molecular Imaging 46:1, pages 139-147.
Crossref
Crossref
Rafid Salim Jabir, Gwo Fuang Ho, Muhammad Azrif Bin Ahmad Annuar & Johnson Stanslas. (2018) Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients. Clinical Breast Cancer 18:5, pages e1173-e1179.
Crossref
Crossref
Nandi Chen, Ying Zhu, Zhenzhen Feng, Qing Wang, Shiya Qin, Ke Quan, Jin Huang, Jianbo Liu, Xiaohai Yang & Kemin Wang. (2018) Selection of Aptamers for Hydrophobic Drug Docetaxel To Improve Its Solubility. ACS Applied Bio Materials 1:1, pages 168-174.
Crossref
Crossref
Deirdre Cronin-Fenton, Anders Kjærsgaard, Mette Nørgaard, Justyna Amelio, Alexander Liede, Rohini K. Hernandez & Henrik T. Sørensen. (2017) Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark. Breast Cancer Research and Treatment 167:2, pages 517-528.
Crossref
Crossref
Hira Choudhury, Bapi Gorain, Manisha Pandey, Santosh Ashok Kumbhar, Rakesh Kumar Tekade, Arun K. Iyer & Prashant Kesharwani. (2017) Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. International Journal of Pharmaceutics 529:1-2, pages 506-522.
Crossref
Crossref
Whasun Lim, Sunwoo Park, Fuller W. Bazer & Gwonhwa Song. (2017) Naringenin-Induced Apoptotic Cell Death in Prostate Cancer Cells Is Mediated via the PI3K/AKT and MAPK Signaling Pathways. Journal of Cellular Biochemistry 118:5, pages 1118-1131.
Crossref
Crossref
Nicholas Chiu, Leonard Chiu, Ronald Chow, Henry Lam, Sunil Verma, Mark Pasetka, Edward Chow & Carlo DeAngelis. (2016) Taxane-induced arthralgia and myalgia: A literature review. Journal of Oncology Pharmacy Practice 23:1, pages 56-67.
Crossref
Crossref
Ricardo Fernandes, Sasha Mazzarello, Brian Hutton, Risa Shorr, Habeeb Majeed, Mohammed FK Ibrahim, Carmel Jacobs, Michael Ong & Mark Clemons. (2016) Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review. Supportive Care in Cancer 24:8, pages 3633-3650.
Crossref
Crossref
Lukas Schwentner, Nadia Harbeck, Susanne Singer, Martin Eichler, Brigitte Rack, Helmut Forstbauer, Arthur Wischnik, Christoph Scholz, Jens Huober, Thomas W.P. Friedl, Tobias Weissenbacher, Kristin Härtl, Marion Kiechle, Wolfgang Janni & Visnja Fink. (2016) Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial. The Breast 27, pages 69-77.
Crossref
Crossref
J. Truong, E.K. Lee, M.E. Trudeau & K.K.W. Chan. (2016) Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Annals of Oncology 27:4, pages 608-618.
Crossref
Crossref
Susana Pereira, Filipa Fontes, Teresa Sonin, Teresa Dias, Maria Fragoso, José M. Castro-Lopes & Nuno Lunet. (2015) Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study. Supportive Care in Cancer 24:4, pages 1571-1581.
Crossref
Crossref
Mathangi Srinivasan, Mehdi Rajabi & Shaker A. Mousa. 2016. Nanobiomaterials in Cancer Therapy. Nanobiomaterials in Cancer Therapy
57
89
.
Keiko Yoshimura & Yoshihiko Furuya. (2014) Changes in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle. SpringerPlus 3:1.
Crossref
Crossref
C. Andersen, M. Rørth, B. Ejlertsen & L. Adamsen. (2014)
Exercise despite pain
- breast cancer patient experiences of muscle and joint pain during adjuvant chemotherapy and concurrent participation in an exercise intervention
. European Journal of Cancer Care 23:5, pages 653-667.
Crossref
Crossref
E. Hall, D. Cameron, R. Waters, P. Barrett-Lee, P. Ellis, S. Russell, J.M. Bliss & P. Hopwood. (2014) Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6year results from the UK TACT trial (CRUK/01/001). European Journal of Cancer 50:14, pages 2375-2389.
Crossref
Crossref
Bryan Hoang, Mark J. Ernsting, Mami Murakami, Elijus Undzys & Shyh-Dar Li. (2014) Docetaxel–carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer. International Journal of Pharmaceutics 471:1-2, pages 224-233.
Crossref
Crossref
L. Eckhoff, A. S. Knoop, M.-B. Jensen, B. Ejlertsen & M. Ewertz. (2013) Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Research and Treatment 142:1, pages 109-118.
Crossref
Crossref
Anna Goc, Samith T Kochuparambil, Belal Al-Husein, Ahmad Al-Azayzih, Shuaib Mohammad & Payaningal R Somanath. (2012) Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer 12:1.
Crossref
Crossref
Hsin-Tien Hsu, Chiun-Sheng Huang, Yi Liu, Marylin J. Dodd, Chiung-Hui Juan, Yu-Hung Lai & Su-Er Guo. (2012) Exercise Behaviors in Breast Cancer Survivors in Taiwan. Cancer Nursing 35:6, pages E48-E56.
Crossref
Crossref
Di Chen, Sreedhar Pamu, Qiuzhi Cui, Tak Hang Chan & Q. Ping Dou. (2012) Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorganic & Medicinal Chemistry 20:9, pages 3031-3037.
Crossref
Crossref
Kyu-pyo Kim, Jin-Hee Ahn, Sung-Bae Kim, Kyung Hae Jung, Dok Hyun Yoon, Jung Shin Lee & Sei-Hyun Ahn. (2012) Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemotherapy and Pharmacology 69:5, pages 1221-1227.
Crossref
Crossref